Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
11.61
-0.88 (-7.05%)
At close: Jun 26, 2026, 4:00 PM EDT
11.85
+0.24 (2.07%)
After-hours: Jun 26, 2026, 7:52 PM EDT
Lyell Immunopharma Employees
Lyell Immunopharma had 161 employees as of December 31, 2025. The number of employees decreased by 139 or -46.33% compared to the previous year.
Employees
161
Change (1Y)
-139
Growth (1Y)
-46.33%
Revenue / Employee
$193
Profits / Employee
-$1,530,472
Market Cap
270.91M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Nautilus Biotechnology | 127 |
| SAB Biotherapeutics | 86 |
| Lineage Cell Therapeutics | 77 |
| Cartesian Therapeutics | 75 |
| InflaRx | 65 |
| Immuneering | 55 |
| Surrozen | 44 |
LYEL News
- 1 day ago - Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 14 days ago - Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress - GlobeNewsWire
- 16 days ago - Lyell Immunopharma Transcript: AGM 2026 - Transcripts
- 18 days ago - Lyell Immunopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 19 days ago - Lyell Immunopharma provides update on safety profile of LYL273 - TheFly
- 19 days ago - Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion - GlobeNewsWire
- 22 days ago - Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress - GlobeNewsWire
- 25 days ago - Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - GlobeNewsWire